Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Psychiatry
•
Psychotic Disorders
•
Internal Medicine
•
General Psychiatry
What is your experience with metformin for improving cognitive impairment in schizophrenia?
In reference to
Shao et al., PMID 37821461.
Answer from: at Community Practice
I have not found that it does much. But there was a recent promising study for using TMS on a particular brain region that is hopeful.
Sign in or Register to read more
26972
Related Questions
What medications do you find helpful to reduce drooling associated with antipsychotics?
Do you observe worsening irritability, mood symptoms, or increased rates of suicidal ideation in patients with Bipolar Disorder who are using hormone birth control including hormone-releasing IUD?
How do you approach the use and titration of Cobenfy in patients with treatment refractory schizophrenia not responding to Clozapine?
What is the best way to manage low systolic blood pressures on clozapine when the patient has failed multiple other antipsychotic trials?
How do you approach treatment-refractory schizophrenia which has not responded to multiple antipsychotic trials including clozapine?
Have you observed adverse mental health side effects in patients who start montelukast?
Do you still consider changing atypical antipsychotics that are working well in children undergoing puberty if the prolactin levels are high but there are no symptoms of drug-induced hyperprolactinemia?
Do you screen for MTHFR polymorphisms in your patients with treatment-resistant depression?
Do you believe that buspirone is ineffective in patients who are previously treated with benzodiazepines?
For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting?